Press Releases in 2018

Check out the latest press releases from Novus. For direct media requests, contact us at novus@novusbio.com.
View Press Releases From: 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007

Bio-Techne Scales Antibody Validation Initiative Using CRISPR Gene Editing Technology Across a Broad Spectrum of Targets

Release Date: 
Tuesday, July 10, 2018 - 00:00

Knockout Validation of Antibodies Confirms Specificity and Ensures Reproducible Results

MINNEAPOLIS, July 10, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a family of brands with a unique and leading portfolio of antibody-based reagents for life science and clinical research, has been validating an extensive and growing number of antibodies using recent advances in gene editing technology.

Bio-Techne Leads the Way in Scientific Support for Autophagy Research

Release Date: 
Thursday, April 26, 2018 - 00:00

MINNEAPOLIS, April 26, 2018 /PRNewswire/ -- Bio-Techne, a family of brands providing a unique portfolio of products and services for basic and clinical research, has a leading role supporting autophagy research.

Autophagy (or "self-eating") is an important basic cellular process by which cell components are degraded by lysosomes or vacuoles and recycled. Autophagy plays a crucial role in human health and disease. Disrupted autophagy has been implicated in Parkinson's disease, type 2 diabetes, cancer, and is now a major target for drug discovery and development.

Bio-Techne Expands RNAscope® ISH Automation - Facilitating Drug Discovery and Development

Release Date: 
Wednesday, March 21, 2018 - 00:00

New and updated assays increase application areas and improve performance

Bio-Techne Acquires Atlanta Biologicals Inc,

Release Date: 
Tuesday, January 2, 2018 - 12:00

MINNEAPOLIS, Jan. 2, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced today that it has acquired all of the stock of Atlanta Biologicals, Inc. and its affiliated company, Scientific Ventures, Inc.. The transaction is financed through available cash on hand.

Bio-Techne

Pages